CXCL12 and acute respiratory distress syndrome: Similar to vehicle treated animals in series 1, P/F in animals treated with 0.7 μmol/kg CXCL12 (3–68) and 0.07 μmol/kg CXCL12 progressively decreased and animals fulfilled criteria for moderate to severe ARDS at t = 300 min (Fig. 2E).